Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update
AbastractBullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus. BP pathogenesis involves autoantibodies against hemidesmosomal proteins BP180 and BP230, leading to detachment at the dermo-epidermal junction as well as blister formation. BP is associated with coexisting comorbidities and drug exposure, and its management often requires high doses or chronic use of systemic glucocorticoids, posing risks of adverse effects....
Source: American Journal of Clinical Dermatology - December 29, 2023 Category: Dermatology Source Type: research
Eosinophil to lymphocyte ratio may predict OCS reduction and change in quality of life (AQLQ) resulting from asthma biological treatment
CONCLUSIONS: Pre-treatment eosinophil-to-lymphocyte ratio may predict oral corticosteroid dose reduction resulting from omalizumab treatment and change in quality of life and asthma control resulting from anti-IL-5 and IL-5R treatment.PMID:38151952 | DOI:10.1080/08923973.2023.2300300 (Source: Immunopharmacology and Immunotoxicology)
Source: Immunopharmacology and Immunotoxicology - December 28, 2023 Category: Allergy & Immunology Authors: Olga Branicka Rados ław Gawlik Joanna Gl ück Source Type: research
The biologic asthma response score
There are 20 million adults in the United States who have asthma, making it the most chronic lung disease in this country.1 Of these, only approximately 10% have severe asthma, but this group has the highest morbidity and mortality, being responsible for approximately 50% of all asthma-related costs.1,2 Since the introduction of omalizumab, the management of severe asthma has been transformed by the availability of biologics that can aid in the personalized management of this condition.3 However, the response to biologics is variable, and there is still a need to better understand on how to best define, predict, and measur...
Source: Annals of Allergy, Asthma and Immunology - December 18, 2023 Category: Allergy & Immunology Authors: Christian Rosas-Salazar, Leonard B. Bacharier Tags: Editorial Source Type: research
Insights from the trends of omalizumab and mepolizumab utilization in patients with asthma: A population-based cohort study using the National Database in Japan
CONCLUSIONS: In Japan, biologics are prescribed more often to older patients with severe asthma compared to those in other countries. Thus, eliminating the regional disparities in asthma treatment by specialists is necessary to provide appropriate medical care to patients with severe asthma.PMID:38101278 | DOI:10.1016/j.resinv.2023.11.003 (Source: Respiratory Care)
Source: Respiratory Care - December 15, 2023 Category: Respiratory Medicine Authors: Keiko Kan-O Tatsuya Noda Hiroaki Ogata Katsunori Masaki Yuichi Nishioka Tomoya Myojin Takeya Adachi Hideaki Morita Tomoaki Imamura Mayumi Tamari Keigo Kainuma ENGAGE NDB Task Force Source Type: research
Insights from the trends of omalizumab and mepolizumab utilization in patients with asthma: A population-based cohort study using the National Database in Japan
CONCLUSIONS: In Japan, biologics are prescribed more often to older patients with severe asthma compared to those in other countries. Thus, eliminating the regional disparities in asthma treatment by specialists is necessary to provide appropriate medical care to patients with severe asthma.PMID:38101278 | DOI:10.1016/j.resinv.2023.11.003 (Source: Respiratory Care)
Source: Respiratory Care - December 15, 2023 Category: Respiratory Medicine Authors: Keiko Kan-O Tatsuya Noda Hiroaki Ogata Katsunori Masaki Yuichi Nishioka Tomoya Myojin Takeya Adachi Hideaki Morita Tomoaki Imamura Mayumi Tamari Keigo Kainuma ENGAGE NDB Task Force Source Type: research
Predictive value of the systemic immune inflammation index and systemic inflammatory response index on omalizumab drug survival in chronic spontaneous urticaria
ConclusionThis study suggests the potential utility of SIRI as a superior predictive indicator for omalizumab’s drug survival in CSU patients compared to SII. Concomitant autoimmune disease or baseline IgE levels did not significantly affect the drug’s effectiveness. (Source: Allergo Journal International)
Source: Allergo Journal International - December 12, 2023 Category: Allergy & Immunology Source Type: research
Progressive clinical effects of the combination omalizumab and HDM - allergen immunotherapy in asthma
CONCLUSION: The combination of HDM SCIT and omalizumab is significantly and progressively reducing ICS use and AX in a 24-month study. The combination is significantly more effective than the single treatments or placebo.PMID:38064236 | DOI:10.1080/02770903.2023.2293057 (Source: Journal of Asthma)
Source: Journal of Asthma - December 8, 2023 Category: Respiratory Medicine Authors: Andrzej Bozek Barbara Rogala Martyna Miodonska Giorgio Walter Canonica Source Type: research
Biomarkers of Autoimmune Chronic Spontaneous Urticaria
AbstractPurposeof ReviewChronic spontaneous urticaria and chronic inducible urticaria (CSU/CindU) are caused by mast cell and basophil activation leading to degranulation and the release of histamine and several other mediators. Three kinds of factors can trigger mast cells in CSU: (1) activation of stimulating receptor(s) on the mast cell membrane, (2) upregulation of certain receptor(s), and (3) intracellular dysregulation in signaling with overexpression of the spleen tyrosine kinase (SYK) or reduced activation of the inhibitory Src homology 2 (SH2)-containing inositol phosphatases (SHIP)-related pathways. In CSU, two m...
Source: Current Allergy and Asthma Reports - December 8, 2023 Category: Allergy & Immunology Source Type: research
Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses
CONCLUSIONS: This study provides novel fundamental data on proteins associated with response to mepolizumab or omalizumab in severe asthma and warrants further validation as potential biomarkers for therapy selection.PMID:38057814 | DOI:10.1186/s12931-023-02620-1 (Source: Respiratory Care)
Source: Respiratory Care - December 7, 2023 Category: Respiratory Medicine Authors: Ayobami Akenroye Tanawin Nopsopon Laura Cho Matthew Moll Scott T Weiss Source Type: research
